Focusing on Task of Reinventing Peptide Drugs Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides Warren P.Levy, Ph.D.
Peptides are among the most biologically relevant molecules known and also among the most productive areas of pharmaceutical R&...
Focusing on Task of Reinventing Peptide Drugs Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides Warren P.Levy, Ph.D.
Peptides are among the most biologically relevant molecules known and also among the most productive areas of pharmaceutical R&...
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations SOUTH SAN FRANCISCO, Calif., June 24 (HSMN NewsFeed) -- Portola Pharmaceuticals, a clinical-stage biopharmaceutical developing best-in-class therapeutics for acute and chronic cardiovascular and inflammatory diseases, today announced that...
Key Challenges and Issues facing the Blood Disorders Market Analysis and Forecasts Report to 2013 Chapter 1: Executive Summary Chapter 2: Blood Diseases and their Treatments 2.1 Functions of Blood 2.1.1 Haemopoiesis 2.1.2 Haemostasis 2.2 Anaemia 2.2.1 Iron Deficiency 2.2.2 Anaemia of Chronic Disease 2.2.3 Megaloblastic Anaemia 2.2.4...
Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial /PRNewswire/ -- Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow(R) Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today.The GRAVITAS trial is designed to evaluate...
Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial SAN DIEGO, June 16 /PRNewswire/ -- Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow(R) Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today.The GRAVITAS trial is...
Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial SAN DIEGO, June 16 /PRNewswire/ -- Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow(R) Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today.The GRAVITAS trial is...
Prasugrel's Bleed Risk Not a Deterrent for Physicians Who Anticipate Its Use, According to Study by GfK Market - Awareness and intent-to-prescribe levels are promising among physicians for the Phase III drug prasugrel, for patients with Acute Coronary Syndrome (ACS) being managed with Percutaneous Coronary Intervention (PCI).The agent is viewed by...
Prasugrel's Bleed Risk Not a Deterrent for Physicians Who Anticipate Its Use, According to Study by GfK Market , 9:00 AM EST News source: Business Wire Awareness and intent-to-prescribe levels are promising among physicians for the Phase III drug prasugrel, for patients with Acute Coronary Syndrome (ACS) being managed with Percutaneous Coronary...
